Amarin Corporation plc (ADR)  

(Public, NASDAQ:AMRN)   Watch this stock  
Find more results for Joseph M Aaron�
+0.02 (1.32%)
Real-time:   11:38AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.51 - 1.56
52 week 0.78 - 2.09
Open 1.54
Vol / Avg. 955,745.00/2.05M
Mkt cap 261.25M
P/E     -
Div/yield     -
EPS -0.31
Shares 174.15M
Beta     -
Inst. own 41%
Mar 3, 2015
Q4 2014 Amarin Corporation PLC Earnings Call - 4:30PM EST - Add to calendar
Mar 3, 2015
Q4 2014 Amarin Corporation PLC Earnings Release - 4:00PM EST - Add to calendar
Jan 15, 2015
Amarin Corporation PLC at JPMorgan Healthcare Conference
Dec 11, 2014
Amarin Corporation PLC at Oppenheimer Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -184.11% -630.82%
Operating margin -176.30% -691.08%
EBITD margin - -678.95%
Return on average assets -53.42% -59.02%
Return on average equity - -
Employees 185 -
CDP Score - -


2 Pembroke House Upper Pembroke Street 28-32, Dublin 2
+353-1-6699020 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Amarin Corporation plc is a biopharmaceutical company with expertise in lipid science focused on the commercialization and development of therapeutics to improve cardiovascular health. The Company�s lead product, Vascepa (known in its development stage as AMR 101), reduces triglyceride levels in adult patients with severe hypertriglyceridemia. The Company is developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol (LDL-C) levels, referred as mixed dyslipidemia. REDUCE-IT is a multi-center, prospective, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effectiveness of Vascepa. The REDUCE-IT study is designed to evaluate the efficacy of Vascepa in reducing major cardiovascular events in an at-risk patient population also receiving statin therapy. The Company completed dosing of AMR102, a fixed dose combination of Vascepa and a leading statin product.

Officers and directors

Lars G. Ekman M.D., Ph.D. Independent Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
John F. Thero CPA President, Chief Executive Officer, Assistant Secretary, Director
Age: 53
Bio & Compensation  - Reuters
Michael J. Farrell Principal Financial Officer and Principal Accounting Officer
Age: 36
Bio & Compensation  - Reuters
Stephen B. Ketchum Ph.D. President - Research and Development, Senior Vice President
Age: 49
Bio & Compensation  - Reuters
Joseph T. Kennedy J.D. Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
Age: 46
Bio & Compensation  - Reuters
Aaron D. Berg Senior Vice President - Marketing and Sales
Bio & Compensation  - Reuters
Joseph S. Zakrzewski Director
Age: 51
Bio & Compensation  - Reuters
David M. Stack Independent Director
Age: 62
Bio & Compensation  - Reuters
James I. Healy M.D., Ph.D. Non-Executive Independent Director
Age: 49
Bio & Compensation  - Reuters
Patrick J. O'Sullivan Non-Executive Independent Director
Age: 72
Bio & Compensation  - Reuters